CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Cisplatin 40 mg/m2 +1 moredrug
Likely dose
Cisplatin 40 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03998696
NCT03998696Phase 4Completed
CompareCT.gov

Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh·interventional·Posted Jun 26, 2019·Updated Jun 28, 2019

In Brief

A Phase 4 clinical trial evaluating Cisplatin 40 mg/m2 and Cisplatin 100 mg/m2 for Head and Neck Squamous Cell Carcinoma. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer. Half of the participants received Cisplatin (40 mg/m2) weekly with radiotherapy, while the other half received Cisplatin (100 mg/m2) thrice weekly with radiotherapy. Radiotherapy continued five days per week for six and half weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma
CountriesBangladesh
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJun 26, 2019
Enrollment StartJul 1, 2017
Primary CompletionJun 30, 2018
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.0 years ago

Interventions

Cisplatin 40 mg/m2drug

Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy

Cisplatin 100 mg/m2drug

Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy